Safety of Shujinjianyao pill in clinical real world: A prospective, observational, multicenter, large-sample study Protocol

Xin Cui, Long Liang, Lianxin Wang, Zhifei Wang, Yuanyuan Li, Yang Gao, Cheng Zhang, Menghua Sun, Shiheng Wang, Jiani Liu, Yue Zhang, Zhibo Wang, Xu Wei, Yanming Xie, Xin Cui, Long Liang, Lianxin Wang, Zhifei Wang, Yuanyuan Li, Yang Gao, Cheng Zhang, Menghua Sun, Shiheng Wang, Jiani Liu, Yue Zhang, Zhibo Wang, Xu Wei, Yanming Xie

Abstract

Background: Low back pain is a common health problem worldwide, which also is a leading cause of long-term disability and has an important effect on the global economy and society. Usually, conservative therapies are used to treat low back pain. As a kind of Chinese patent medicine, Shujinjianyao pill (SJJYP) has a great curative effect on low back pain. However, its safety has not been studied yet. Therefore, we carried out this clinical trial to observe the safety of SJJYP in the real world.

Methods: First, participants need to meet the medication standards according to inclusion and exclusion criteria. Then, participants are conducted safety examination before taking SJJYP. After qualified screening, participants can be enrolled into the group. Second, all enrolled participants will receive SJJJYP for a period of 4 weeks. During the observation period, participants need to return to the hospital for a subsequent visit after 2 weeks of medication, and come to the hospital for safety check after 4 weeks of medication. Third, telephone follow-up is used to investigate any participants' physical discomfort after 6 to 8 weeks (2-4 weeks after medication withdrawal). After all these steps are completed, clinical observation is finished. If any adverse events occur during this process, we will record them in time. When serious adverse events occur, we will use nested case-control study to explore the causes and mechanisms.

Discussion: This study will obtain the safety results of SJJYP in clinical real world, which will offer a scientific basis for clinicians in the treatment of low back pain, and also provide a methodological basis for the safety study of other medicines.

Trial registration: ClinicalTrial.gov registration number is NCT03598153. This study was approved by the ethics committee of Wangjing hospital, China Academy of Chinese Medical Sciences (WJEC-KT-2018-012-P002).

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of the clinical trial.

References

    1. Hoy D, Brooks P, Blyth F, et al. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol 2010;24:769–81.
    1. Dionne CE, Dunn KM, Croft PR. Does back pain prevalence really decrease with increasing age? A systematic review. Age Ageing 2006;35:229–34.
    1. Rapoport J, Jacobs P, Bell NR, et al. Refining the measurement of the economic burden of chronic diseases in Canada. Chronic Dis Can 2004;25:13–21.
    1. Deyo RA, Cherkin D, Conrad D, et al. Cost, controversy, crisis: low back pain and the health of the public. Annu Rev Public Health 1991;12:141–56.
    1. Patrick N, Emanski E, Knaub MA. Acute and chronic low back pain. Med Clin North Am 2014;98:777–89. xii.
    1. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147:478–91.
    1. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine (Phila Pa 1976) 1995;20:11–9.
    1. US NCFH. Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville (MD): National Center for Health Statistics (US), 2014.
    1. Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012;64:2028–37.
    1. Balague F, Mannion AF, Pellise F, et al. Non-specific low back pain. Lancet 2012;379:482–91.
    1. Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001;344:363–70.
    1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743–800.
    1. Lidgren L. The bone and joint decade 2000-2010. Bull World Health Organ 2003;81:629.
    1. Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am 2006;88 suppl 2:21–4.
    1. Tavee JO, Levin KH. Low back pain continuum (Minneap Minn) 23 (2, selected topics in outpatient neurology) 2017. 467–86.
    1. Konstantinou K, Dunn KM. Sciatica: review of epidemiological studies and prevalence estimates. Spine (Phila Pa 1976) 2008;33:2464–72.
    1. Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet 2018;391:2368–83.
    1. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline From the American College of Physicians. Ann Intern Med 2017;166:514–30.
    1. UK., NGC. Low Back Pain and Sciatica in Over 16 s: Assessment and Management. London: National Institute for Health and Care Excellence (UK); 2016.
    1. Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J 2018;27:2791–803.
    1. Verhagen AP, Downie A, Popal N, et al. Red flags presented in current low back pain guidelines: a review. Eur Spine J 2016;25:2788–802.
    1. Yuan QL, Guo TM, Liu L, et al. Traditional Chinese medicine for neck pain and low back pain: a systematic review and meta-analysis. PLoS One 2015;10:e0117146.
    1. Yuan WA, Huang SR, Guo K, et al. Integrative TCM conservative therapy for low back pain due to lumbar disc herniation: a randomized controlled clinical trial. Evid Based Complement Alternat Med 2013;2013:309831.
    1. Chen BL, Guo JB, Zhang HW, et al. Surgical versus non-operative treatment for lumbar disc herniation: a systematic review and meta-analysis. Clin Rehabil 2018;32:146–60.
    1. Xie L, Wu QF, Wang XD, et al. Effect of Shujinjianyao pill on articular cartilage and serum cytokines in rats with osteoarthritis. Pharmacy Today 2014;24:862–5. (In Chinese).
    1. Li Q, Liu WD, Yu PF. Shujinjianyao pill in the treatment of sciatica (liver-kidney deficiency syndrome) caused by lumbar disc herniation. Journal of Chinese Medicinal Materials 2018;41:737–9. (In Chinese).
    1. Shi HC, Ou HY, He FL, et al. Effects of Shujinjianyao pill on sciatic nerve tissue and serum cytokines in rats with sciatica. China Medical Herald 2017;14:11–5. (In Chinese).
    1. Letter from National Medical Products Administration for Soliciting Opinions on “Notice on Promoting Manufacturing Enterprises to Carry out Key Drug Monitoring Work (Draft for Soliciting Opinions)”. [EB/OL] (2013-03-25) [2019-07-01]. Available at:

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅